Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Receivables: 2016-2024

Historic Receivables for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $10.8 million.

  • Zevra Therapeutics' Receivables rose 116.19% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year increase of 34.09%. This contributed to the annual value of $10.8 million for FY2024, which is 41.82% down from last year.
  • As of FY2024, Zevra Therapeutics' Receivables stood at $10.8 million, which was down 41.82% from $18.6 million recorded in FY2023.
  • In the past 5 years, Zevra Therapeutics' Receivables ranged from a high of $18.6 million in FY2023 and a low of $1.6 million during FY2021.
  • For the 3-year period, Zevra Therapeutics' Receivables averaged around $13.0 million, with its median value being $10.8 million (2024).
  • Per our database at Business Quant, Zevra Therapeutics' Receivables spiked by 475.72% in 2022 and then plummeted by 41.82% in 2024.
  • Over the past 5 years, Zevra Therapeutics' Receivables (Yearly) stood at $2.7 million in 2020, then tumbled by 39.80% to $1.6 million in 2021, then soared by 475.72% to $9.4 million in 2022, then soared by 97.97% to $18.6 million in 2023, then crashed by 41.82% to $10.8 million in 2024.